Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice

Can genetic markers be used to predict anti-TNF response? A cohort was established to identify SNPs associated with anti-TNF therapy in patients with inflammatory bowel disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Crohn's Disease Colitis Colitis, Ulcerative Colonic Diseases Crohn Disease Digestive System Diseases Gastroenteritis Gastrointestinal Diseases Inflammatory Bowel Disease Inflammatory Bowel Diseases Intestinal Diseases Ulcerative Colitis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

CD or UC, treated with anti-TNF

Exclusion criteria

Missing data

Treatment and study plan

infliximab and adalimumab

Biological

In this retrospective, observational study, no interventions were undertaken by the researchers.

Other names: remicade and humira, anti-TNF

Primary outcomes

3-step scale

Time frame: 22 weeks

Best response within 22 weeks

Sponsors and collaborators

Lead sponsor

Regionshospitalet Viborg, Skive

Other

Registry information

Important dates

Study start: 2009
Primary completion: 2011
Study completion: 2011
First posted: Dec 22, 2014
Registry last updated: Dec 23, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed